Califf Supports Combo Products Pathway At Confirmation Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's concepts for new pathway could be ready for congressional scrutiny within a year.
You may also be interested in...
Califf Confirmation Hearing Round Two: Industry Ties Once Again May Bark Loud, Bite Lightly
The cardiologist seeking another term as FDA commissioner has been working in the pharma industry since leaving the post, but Senators have tended not to question nominee's work history extensively during previous confirmation hearings.
Califf Confirmation Hearing Round Two: Industry Ties Once Again May Bark Loud, Bite Lightly
The cardiologist seeking another term as FDA commissioner has been working in the pharma industry since leaving the post, but Senators have tended not to question nominee's work history extensively during previous confirmation hearings.
Combo Products Won't Get Special Review Pathway At US FDA Anytime Soon
Jeffrey Shuren and Janet Woodcock tell Senate committee that agency is more concerned with implementing combination product provisions of the 21st Century Cures Act.